Literature DB >> 24599439

Thrombosis in brain tumors.

Jasmin T Jo1, David Schiff2, James R Perry3.   

Abstract

Venous thromboembolism (VTE) is common in patients with brain tumors, occurring in up to 30% of patients with high-grade glioma and up to 20% of those with brain metastasis and primary central nervous system (CNS) lymphoma. The risk is correlated with higher grade malignancies and is directly associated with the production of the potent procoagulant, tissue factor (TF). Upregulation of TF influences both the coagulation pathway and oncogenic signaling mechanisms important for cancer progression. The risk of intracranial hemorrhage with the use of anticoagulants complicates the management of VTE in patients with brain tumor. We discuss the recommended anticoagulants used for initial and long-term treatment of established VTE, including unfractionated heparin, low-molecular-weight heparin (LMWH), and warfarin. Therapeutic anticoagulation, particularly LMWH followed by secondary prophylaxis, is generally safe and effective in the treatment of VTE, including patients on antiangiogenic agents. Anticoagulation also reduces the risk of VTE during the perioperative period. However, despite the high risk of VTE throughout the course of disease, present data do not support routine thromboprophylaxis in brain tumor patients. Further investigation regarding the mechanisms underlying the hypercoagulable state of patients with brain tumors and the potential role of the factors and products of thrombogenesis as biomarkers for risk stratification will be useful in identification and management of patients at risk of developing VTE. Novel oral anticoagulants that directly inhibit thrombin such as dabigatran or factor Xa, including rivaroxaban and apixaban have several potential advantages; however, due to limited data in the cancer population, the use of these newer oral anticoagulants is not currently recommended for patients with malignancy and VTE. Recent studies have explored the role of anticoagulants as anticancer agents, which may contribute to cancer treatment in the future. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2014        PMID: 24599439     DOI: 10.1055/s-0034-1370791

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  21 in total

1.  Prevention and treatment of venous thromboembolism in patients with solid brain neoplasms: results of a survey among Italian physicians.

Authors:  Nicola Mumoli; Stefano Barco; Marco Cei; Matteo Giorgi-Pierfranceschi; Mauro Campanini; Andrea Fontanella; Walter Ageno; Francesco Dentali
Journal:  Intern Emerg Med       Date:  2016-11-23       Impact factor: 3.397

Review 2.  Managing Disease and Therapy-Related Complications in Patients with Central Nervous System Tumors.

Authors:  Jeffrey J Raizer; Karan S Dixit
Journal:  Curr Treat Options Oncol       Date:  2015-08

Review 3.  Medical management of brain tumors and the sequelae of treatment.

Authors:  David Schiff; Eudocia Q Lee; Lakshmi Nayak; Andrew D Norden; David A Reardon; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2014-10-30       Impact factor: 12.300

Review 4.  Venous Thrombotic Events and Anticoagulation in Brain Tumor Patients.

Authors:  Maria Diaz; Jasmin Jo
Journal:  Curr Oncol Rep       Date:  2022-02-18       Impact factor: 5.075

Review 5.  Therapeutic Anticoagulation in Patients with Primary Brain Tumors or Secondary Brain Metastasis.

Authors:  Richard J Lin; David L Green; Gunjan L Shah
Journal:  Oncologist       Date:  2017-11-20

Review 6.  Venous Thromboembolism in Brain Tumors: Risk Factors, Molecular Mechanisms, and Clinical Challenges.

Authors:  Julia Riedl; Cihan Ay
Journal:  Semin Thromb Hemost       Date:  2019-04-30       Impact factor: 4.180

7.  Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism.

Authors:  Julia Riedl; Matthias Preusser; Pegah Mir Seyed Nazari; Florian Posch; Simon Panzer; Christine Marosi; Peter Birner; Johannes Thaler; Christine Brostjan; Daniela Lötsch; Walter Berger; Johannes A Hainfellner; Ingrid Pabinger; Cihan Ay
Journal:  Blood       Date:  2017-01-10       Impact factor: 22.113

8.  Management of venous thromboembolism in high-grade glioma: Does low molecular weight heparin increase intracranial bleeding risk?

Authors:  Jasmin Jo; Joseph Donahue; Guneet Sarai; Gina Petroni; David Schiff
Journal:  Neuro Oncol       Date:  2022-03-12       Impact factor: 13.029

Review 9.  Intracranial hemorrhage in setting of glioblastoma with venous thromboembolism.

Authors:  Michael Nabil Khoury; Symeon Missios; Natasha Edwin; Susmita Sakruti; Gene Barnett; Glen Stevens; David M Peereboom; Alok A Khorana; Manmeet S Ahluwalia
Journal:  Neurooncol Pract       Date:  2015-08-25

10.  Risk of Venous Thromboembolism in Grade II-IV Gliomas as a Function of Molecular Subtype.

Authors:  Maria Diaz; Jasmin Jo; Mark Smolkin; Sarah Jane Ratcliffe; David Schiff
Journal:  Neurology       Date:  2020-12-22       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.